Published in Clin Cancer Res on October 01, 2005
Radioimmunotherapy with Tenarad, a 131I-labelled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging (2014) 1.45
Filled and glycosylated carbon nanotubes for in vivo radioemitter localization and imaging. Nat Mater (2010) 1.45
Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology. J Clin Oncol (2012) 1.39
Three-dimensional imaging-based radiobiological dosimetry. Semin Nucl Med (2008) 1.31
Positron emission tomography tracers for imaging angiogenesis. Eur J Nucl Med Mol Imaging (2010) 1.15
Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis. Arthritis Res Ther (2009) 1.12
Exon array analysis using re-defined probe sets results in reliable identification of alternatively spliced genes in non-small cell lung cancer. BMC Genomics (2010) 1.01
(124)I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of (131)I-L19-SIP radioimmunotherapy. Eur J Nucl Med Mol Imaging (2009) 0.99
Antibody-mediated delivery of IL-10 inhibits the progression of established collagen-induced arthritis. Arthritis Res Ther (2007) 0.99
Radioimmunotherapy of solid tumors: searching for the right target. Curr Drug Deliv (2011) 0.96
A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels. Br J Cancer (2011) 0.94
Human monoclonal antibodies targeting carbonic anhydrase IX for the molecular imaging of hypoxic regions in solid tumours. Br J Cancer (2009) 0.87
The antibody-based targeted delivery of TNF in combination with doxorubicin eradicates sarcomas in mice and confers protective immunity. Br J Cancer (2013) 0.84
Characterisation and radioimmunotherapy of L19-SIP, an anti-angiogenic antibody against the extra domain B of fibronectin, in colorectal tumour models. Br J Cancer (2007) 0.81
Antibody library-based tumor endothelial cells surface proteomic functional screen reveals migration-stimulating factor as an anti-angiogenic target. Mol Cell Proteomics (2008) 0.81
Marine Antibody-Drug Conjugates: Design Strategies and Research Progress. Mar Drugs (2017) 0.75
Multimodality Imaging in Tumor Angiogenesis: Present Status and Perspectives. Int J Mol Sci (2017) 0.75
Molecular imaging in drug development. Nat Rev Drug Discov (2008) 4.06
Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol (2008) 3.67
Tumor targeting by an aptamer. J Nucl Med (2006) 2.68
STANDARD CUT RATE 25-GAUGE VITRECTOMY VERSUS ULTRAHIGH-SPEED 25-GAUGE SYSTEM IN CORE VITRECTOMY: A Randomized Clinical Trial. Retina (2016) 1.94
Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature. J Nucl Med (2006) 1.62
Application of locked nucleic acids to improve aptamer in vivo stability and targeting function. Nucleic Acids Res (2004) 1.54
Radiopharmaceutical therapy of patients with metastasized melanoma with the melanin-binding benzamide 131I-BA52. J Nucl Med (2013) 1.53
Novel approach in radionuclide tumor therapy: dose enhancement by high Z-element contrast agents. Cancer Biother Radiopharm (2006) 1.42
Design, construction, and characterization of a large synthetic human antibody phage display library. Proteomics (2005) 1.42
Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res (2003) 1.31
Synthesis, 18F-labeling, and in vitro and in vivo studies of bombesin peptides modified with silicon-based building blocks. Bioconjug Chem (2008) 1.28
Specific PET imaging of xC- transporter activity using a ¹⁸F-labeled glutamate derivative reveals a dominant pathway in tumor metabolism. Clin Cancer Res (2011) 1.27
Silicon-based building blocks for one-step 18F-radiolabeling of peptides for PET imaging. Angew Chem Int Ed Engl (2008) 1.21
Exploratory clinical trial of (4S)-4-(3-[18F]fluoropropyl)-L-glutamate for imaging xC- transporter using positron emission tomography in patients with non-small cell lung or breast cancer. Clin Cancer Res (2012) 1.17
Direct one-step 18F-labeling of peptides via nucleophilic aromatic substitution. Bioconjug Chem (2009) 1.14
Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn's disease. Mol Ther (2012) 1.13
(4S)-4-(3-18F-fluoropropyl)-L-glutamate for imaging of xC transporter activity in hepatocellular carcinoma using PET: preclinical and exploratory clinical studies. J Nucl Med (2012) 1.07
4-[18F]fluoroglutamic acid (BAY 85-8050), a new amino acid radiotracer for PET imaging of tumors: synthesis and in vitro characterization. J Med Chem (2010) 1.07
Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours. Eur J Nucl Med Mol Imaging (2010) 1.06
Plasma pharmacokinetics, whole-body distribution, metabolism, and radiation dosimetry of 68Ga bombesin antagonist BAY 86-7548 in healthy men. J Nucl Med (2013) 1.03
In vivo imaging of prostate cancer using [68Ga]-labeled bombesin analog BAY86-7548. Clin Cancer Res (2013) 1.03
Imaging of tumor angiogenesis using 99mTc-labeled human recombinant anti-ED-B fibronectin antibody fragments. J Nucl Med (2006) 1.00
(124)I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of (131)I-L19-SIP radioimmunotherapy. Eur J Nucl Med Mol Imaging (2009) 0.99
Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine. J Nucl Med (2009) 0.96
(S)-4-(3-18F-fluoropropyl)-L-glutamic acid: an 18F-labeled tumor-specific probe for PET/CT imaging--dosimetry. J Nucl Med (2013) 0.94
18F-labeled bombesin analog for specific and effective targeting of prostate tumors expressing gastrin-releasing peptide receptors. J Nucl Med (2011) 0.94
Preclinical characterization of a novel class of 18F-labeled PET tracers for amyloid-β. J Nucl Med (2012) 0.93
Identification and evaluation of a new tumor cell-binding peptide, FROP-1. J Nucl Med (2007) 0.91
Small-animal PET of tumor angiogenesis using a (76)Br-labeled human recombinant antibody fragment to the ED-B domain of fibronectin. J Nucl Med (2007) 0.90
Bispecific antibody pretargeting of tumor neovasculature for improved systemic radiotherapy of solid tumors. Clin Cancer Res (2006) 0.89
Preclinical evaluation of an 131I-labeled benzamide for targeted radiotherapy of metastatic melanoma. Cancer Res (2010) 0.88
Somatostatin receptor-binding peptides suitable for tumor radiotherapy with Re-188 or Re-186. Chemistry and initial biological studies. J Med Chem (2007) 0.86
Novel chemically modified analogues of neuropeptide Y for tumor targeting. Bioconjug Chem (2008) 0.85
Iatrogenic retinal breaks in 25-gauge vitrectomy under air compared with the standard 25-gauge system for macular diseases. Retina (2014) 0.85
Targeted radiotherapy of prostate cancer with a gastrin-releasing peptide receptor antagonist is effective as monotherapy and in combination with rapamycin. J Nucl Med (2013) 0.85
In vitro and in vivo characterization of novel 18F-labeled bombesin analogues for targeting GRPR-positive tumors. Bioconjug Chem (2010) 0.83
MIA (melanoma inhibitory activity) promoter mediated tissue-specific suicide gene therapy of malignant melanoma. Cancer Gene Ther (2004) 0.82
Melanoma uptake of (99m)Tc complexes containing the N-(2-diethylaminoethyl)benzamide structural element. J Med Chem (2002) 0.82
Molecular targeting of angiogenesis for imaging and therapy. Eur J Nucl Med Mol Imaging (2004) 0.82
Studies toward the development of new silicon-containing building blocks for the direct (18)F-labeling of peptides. J Med Chem (2013) 0.80
MO tripeptide diastereomers (M=99/99mTc, Re): models to identify the structure of 99mTc peptide targeted radiopharmaceuticals. Inorg Chem (2007) 0.79
Dose enhancement through combining internalizing radiation and contrast media. Cancer Biother Radiopharm (2006) 0.78
Prevention of carotid artery restenosis after sirolimus-coated stent implantation in pigs. Stroke (2005) 0.78
Preclinical evaluation of BAY 1075553, a novel (18)F-labelled inhibitor of prostate-specific membrane antigen for PET imaging of prostate cancer. Eur J Nucl Med Mol Imaging (2013) 0.78
Synthesis and radiopharmacological evaluation of a high-affinity and metabolically stabilized 18F-labeled bombesin analogue for molecular imaging of gastrin-releasing peptide receptor-expressing prostate cancer. Nucl Med Biol (2013) 0.78
Targeting of endothelin receptors for molecular imaging of atherosclerosis in rabbits. J Nucl Med (2002) 0.77
Unexpected observation of concentration-dependent dissociation rates for antibody-antigen complexes and other macromolecular complexes in competition experiments. J Immunol Methods (2003) 0.76
Design, synthesis, and initial evaluation of a high affinity positron emission tomography probe for imaging matrix metalloproteinases 2 and 9. J Med Chem (2013) 0.75
Investigations into the synthesis, radiofluorination and conjugation of a new [¹⁸F]fluorocyclobutyl prosthetic group and its in vitro stability using a tyrosine model system. Bioorg Med Chem (2012) 0.75
TRANSCONJUNCTIVAL NONVITRECTOMIZING VITREOUS SURGERY VERSUS 25-GAUGE VITRECTOMY IN PATIENTS WITH EPIRETINAL MEMBRANE: A Prospective Randomized Study. Retina (2015) 0.75
Reduction of intimal hyperplasia with Re-188-labeled stents in a rabbit model at 7 and 26 weeks: an experimental study. Cardiovasc Intervent Radiol (2005) 0.75
Correlation of preoperative retinal pigment epithelium status with foveal microstructure in repaired macular holes. Ophthalmologica (2014) 0.75
Preclinical evaluation of technetium 99m-labeled P1827DS for infection imaging and comparison with technetium 99m IL-8. Nucl Med Biol (2007) 0.75
Non-vitrectomizing surgery for idiopathic macular pucker using a 25-gauge synergetics high-flow infusion with a 27-gauge light (Photon II, Synergetics USA, Inc.). Int Ophthalmol (2009) 0.75